Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia., Shih, Alan H., Meydan Cem, Shank Kaitlyn, Garrett-Bakelman Francine E., Ward Patrick S., Intlekofer Andrew M., Nazir Abbas, Stein Eytan M., Knapp Kristina, Glass Jacob, et al. , Cancer Discov, 2017 May, Volume 7, Issue 5, p.494-505, (2017)

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia., Rampal, Raajit, Alkalin Altuna, Madzo Jozef, Vasanthakumar Aparna, Pronier Elodie, Patel Jay, Li Yushan, Ahn Jihae, Abdel-Wahab Omar, Shih Alan, et al. , Cell Rep, 2014 Dec 11, Volume 9, Issue 5, p.1841-1855, (2014)

Induction of sarcomas by mutant IDH2., Lu, Chao, Venneti Sriram, Akalin Altuna, Fang Fang, Ward Patrick S., Dematteo Raymond G., Intlekofer Andrew M., Chen Chong, Ye Jiangbin, Hameed Meera, et al. , Genes Dev, 2013 Sep 15, Volume 27, Issue 18, p.1986-98, (2013)

IDH mutation impairs histone demethylation and results in a block to cell differentiation., Lu, Chao, Ward Patrick S., Kapoor Gurpreet S., Rohle Dan, Turcan Sevin, Abdel-Wahab Omar, Edwards Christopher R., Khanin Raya, Figueroa Maria E., Melnick Ari, et al. , Nature, 2012 Feb 15, Volume 483, Issue 7390, p.474-8, (2012)

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation., Figueroa, Maria E., Abdel-Wahab Omar, Lu Chao, Ward Patrick S., Patel Jay, Shih Alan, Li Yushan, Bhagwat Neha, Vasanthakumar Aparna, Fernandez Hugo F., et al. , Cancer Cell, 2010 Dec 14, Volume 18, Issue 6, p.553-67, (2010)